Antibody-Drug Conjugates (ADCs) represent a novel type of therapeutic that uses the specificity of monoclonal antibodies to target a tumor-specific antigen and deliver a payload of small cytotoxic molecules to the tumor. Using Gyrolab® xP workstation, a generic IgG assay and an assay to measure payloads of ADCs was quickly developed in parallel.
This Application Note shows how Gyrolab xP workstation supported high productivity for ADC development in both toxicology (non-GLP) studies and subsequent regulated studies
